1. Racaniello,V.R., C.L. Mendelsohn, M. Morrison, M. Freistadt, G. Kaplan, E. Moss, and R.Ren. 1990. Molecular genetics of cellular receptors forpoliovirus. In: "Positive StrandRNA Viruses" (M.A. Brinton and F.X. Heinz, eds). American Society for Microbiology,Washington, DC. pp. 278-286.
2. Ren,R., E. G. Moss, V. R. Racaniello. 1991. Identification of twodeterminants that attenuate vaccine-related type 2 poliovirus. J. Virol. 65:1377-1382.
3. Newlon,C. S., L. R. Lipchitz, I. Collins, A. Deshpande, R. J. Devenish, R. P. Green,H. L. Klein, T. G Palzkill, R. Ren, S. Synn, and S. T. Woody. 1991. Analysis of a circular derivative ofSaccharomyces cerevisiae chromosome III: A physical map and identification andlocation of ARS elements. Genetics. 129: 343-357.
4. Racaniello,V.R., E. Moss, G. Kaplan, R. Ren. 1991. Interaction of polioviruswith its immunoglobulin-like cell receptor. In: "Microbial Adhesion" (M. Hook and L. Switalski, eds)Springer Verlag, Berlin.
5. Ren,R., V. R. Racaniello. 1992. Humanpoliovirus receptor gene expression and poliovirus tissue tropism in transgenicmice. J. Virol. 66: 296-304.
6. Ren,R., V. R. Racaniello. 1992. Poliovirusspreads from muscle to the central nervous system by neural pathways. J.Infect. Dis. 166: 747-752
7. Racaniello,V.R., R. Ren, M. Bouchard. 1992. Poliovirus attenuation and pathogenesis in atransgenic mouse model for poliomyelitis. Develop. Biol. Standard. 78:105-112.
8. Ren,R., B. J. Mayer, P. Ciccheti, and D. Baltimore. 1993. Identification of a ten-amino acid proline-rich SH3 binding site.Science. 259: 1157-1161. (the third-most-frequently cited paper in 1993,Science Watch. 5[1]:1).
9. Mayer,B. J., R. Ren, K. L. Clark, D. Baltimore. 1993. A putative modular domainpresent in diverse signaling proteins. Cell. 73: 629-630.
10. Ren,R., Z. Ye, D. Baltimore. 1994. Ablprotein-tyrosine kinase selects Crk adapter as a substrate using SH3 bindingsites. Genes Dev. 8: 783-795
11. Songyang,Z., S. E. Shoelson, J. McGlade, P. Olivier, T. Pawson, R. X. Bustelo, H.Hanafusa, T. Yi, R. Ren, D. Baltimore, S. Ratnofsky, R. A. Feldman, L. C.Cantley. 1994. Specific motifs recognized by the SH2 domains of csk, 3BP2,fes/fpd, Grb2, SHPTP1, SHC, Syk and vav. Mol. Cell. Biol. 14: 2777-2785
12. Feller,S. M., R. Ren, H. Hanafusa, and D. Baltimore. 1994. SH2 and SH3 domains insignal transduction - the interactions of Crk and Abl. TIBS. 19:453-458.
13. Racaniello,V.R., R. Ren. 1994. Transgenic mice and the pathogenesis of poliomyelitis. ArchVirol Suppl. 9:79-86.
14. Cohen,G., R. Ren, D. Baltimore. 1995. Modular binding domains in signal transduction.Cell: 80:237-48.
15. BaltimoreD; Ren R; Cheng G; Alexandropoulos K; Cicchetti P. 1995. A nuclear tyrosine kinase becomes acytoplasmic oncogene. Ann N Y Acad Sci 758:339-344.
16. Kharbanda,S., R. Ren (co-first-author), P. Pandey, T. D. Shafman, J. Kyriakis, R. R.Weichselbaum, D. Kufe. 1995. Activation of the c-Abl tyrosine kinase in the stress response toDNA-damage agents. Nature. 376: 785-788
17. Racaniello,V. R., R. Ren. 1996. Poliovirus biology and pathogenesis. In: “Transgenic Model of Human Viral and ImmunologicalDisease” (F. V. Chisari and M. B. A. Oldstane, eds). Springer-Verlag, Berlin Heidelberg New York.pp. 305-326.
18. Freeman,N. L., K. A. Mintzer, T. Lila, Z. Chen, A. J. Pahk, R. Ren, and J. Field. 1996. A domain containing a conserved SH3 binding site on the Saccharomycescerevisiae cyclase associated proteinmodulates cytoskeletal interactions and RAS signaling. Mol. Cell. Biol. 16:548-556
19. KharbandaS; P. Pandey; R. Ren; B. Mayer; L. Zon; D. Kufe. 1996. c-Abl activation regulates induction of theSEK1/stress-activated protein kinase pathway in the cellular response to1-beta-D-arabinofuranosylcytosine. J Biol. Chem. 270: 30278-81
20. Kharbanda,S., A. Bharti, D. Pei, J. Wang, P. Pandey, R. Ren, R. Weichselbaum, C. Walsh,and D. Kufe. 1996. The stress responseto ionizing radiation involves c-Abl-Dependent phosphorylation of SHPTP1. Proc. Natl. Acad. Sci. USA. 93: 6898-901
21. Holmes,T. C., D. A. Fadool, R. Ren, and I. B. Levitan. 1996. Association of Src tyrosine kinase with a human potassium channelmediated by SH3 domain. Science. 274: 2089-91
22. Chen,M., H., She, E. M., Davis, C. M., Spicer, L., Kim, R., Ren, M. M., Le Beau, W.,Li. 1998. Identification of Nck family genes, chromosomal localization,expression, and signaling specificity. J. Biol. Chem. 273: 25171
23. Zhang,X. and R. Ren. 1998. Bcr-Abl efficiently induces a myeloproliferative diseaseand production of excess IL-3 and GM-CSF in mice: a novel model for chronicmyelogenous leukemia. Blood. 92: 3829-3840
24. Skourides,P. A., Perera, S. A., and R. Ren. 1999. Polarized distribution of Bcr-Abl inmigrating myeloid cells and co-localization of Bcr-Abl and its target proteins.Oncogene. 18: 1165-1176
25. Gross,A., X. Zhang, and R. Ren. 1999. Bcr-Ablwith an SH3 deletion retains the ability to induce a myeloproliferative diseasein mice, yet c-Abl activated by SH3 deletion induces only lymphoid malignancy.Mol. Cell. Biol. 19: 6918-6928
26. Hao,S. X., and R. Ren. 2000. Expression of ICSBP is downregulated in Bcr-Abl-inducedmurine CML-like disease, and forced coexpression of ICSBP inhibits theBcr-Abl-induced myeloproliferative disorder. Mol. Cell. Biol. 20: 1149-1161.
27. Cuenco,G. M., G. Nucifora, and R. Ren. 2000.Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML)in mice: a novel model for human AML. Proc. Natl. Acad. Sci. USA. 97:1760-1765.
28. GrossA. W. and R. Ren. 2000. Bcr-Abl has a greater intrinsic capacity than v-Abl toinduce the neoplastic expansion of myeloid cells in vivo. Oncogene. 19:6286-6296
29. ZhangX, R. Wong, S. X. Hao, W. S. Pear, and R. Ren. 2001. The SH2 domain of Bcr-Abl is not required to induce a murinemyeloproliferative disease; however, SH2 signaling influences disease latencyand phenotype. Blood. 97: 277-287.
30. ZhangX, R. Subrahmanyam, R. Wong, A. W. Gross and R. Ren. 2001. The NH2-terminalcoiled-coil domain and tyrosine 177 play important roles in induction of amyeloproliferative disease in mice by Bcr-Abl. Mol. Cell. Biol. 21: 840-853
31. Cuenco,M. G. and R. Ren. 2001. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blockingmyeloid differentiation and rapid induction of an Acute Myelogenous Leukemia.Oncogene. 20:8236-8248
32. He,Y., J. A. Wertheim, L. Xu, J. P. Miller, F. G. Karnell, J. K. Choi, R. Ren, andW. S. Pear. 2002. The coiled-coildomain and Tyr177 of bcr are required to induce a murine chronic myelogenousleukemia-like disease by bcr/abl. Blood.99: 2957-2968.
33. Ren,R. 2002. Dissecting the molecular mechanism of chronic myelogenous leukemiausing murine models. Leukemia and Lymphoma. 8: 1549-1561
34. Ren,R. 2002. The molecular mechanism of chronic myelogenous leukemia and itstherapeutic implications: studies in a murine model. Oncogene. 21: 8629-8642.
35. Wertheim,J. A., S. A. Perera, D. Hammer, R. Ren, D. Boettiger and W. S. Pear. 2003. Localization of BCR-ABL to F-actinregulates cell adhesion but does not attenuate CML development. Blood.102:2220-8
36. Dinulescu,D. M., L. J. Wood, L. Shen, M. Loriaux, C. L. Corless, A. W. Gross, R. Ren, M.W..N. Deininger & B. J. Druker. 2003. c-CBL is not required for leukemiainduction by Bcr-Abl in mice. Oncogene. 22:8852-60
37. Ren,R. 2003. Overriding BCR/ABL mitotic signal by ICSBP-induced differentiation.Inside blood, Blood. 102:4251-52
38. Cuenco,G. M. and R. Ren. 2004. Both AML1 andEVI1 oncogenic components are required to the cooperation of AML1/MDS1/EVI1with BCR/ABL in induction of acute myelogenous leukemia in mice. Oncogene.23:569-79
39. Ren,R. 2004. Modeling the dosage effect of oncogenes in leukemogenesis. CurrentOpinion in Hematology. 11:25-34
40. Ren,R. 2004. Restraing CML by adhesives. Blood. 104:1917-18
41. Ren,R. 2005. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenousleukaemia. Nature Reviews Cancer. 5(3):172-83.
42. Ren,R. 2005. Oncogenic forms of Abl family kinases. in "Abl family kinases indevelopment and disease" (A. Koleske, ed). Landes Publishing.
43. Parikh,C. R. Subrahmanyam and R. Ren. 2006. Oncogenic NRAS rapidly and efficientlyinduces CMML- and AML-like diseases in mice. Blood. 108:2349-57.
44. Cuiffo,B. and R. Ren. 2006. Models of hematopoietic malignancies: chronic myeloidleukemia. Drug Discovery Today: Disease Models. 3:183-189
45. Shackelford,D., C. Kenific, A. Blusztajn, S. Waxman and R. Ren. 2006. Targeted Degradationof the AML1/MDS1/EVI1 oncoprotein by Arsenic Trioxide. Cancer Research.66:11360-11369
46. YanM, JK Luo, KJ Ritchie, I Sakai, K Takeuchi, R Ren, DE Zhang. 2007. Ubp43regulates BCR-ABL leukemogenesis via the Type I interferon receptor signaling.Blood. 110:305-12.
47. Parikh,C., R. Subrahmanyam and R. Ren. 2007. Oncogenic NRAS, KRAS and HRAS exhibitdifferent leukemogenic potentials in mice. Cancer Research. 67:7139-46
48. Zhang,S. J., L. Y. Ma, Q. H. Huang, G. Li, B. W. Gu, X. D. Gao, J. Y. Shi, Y. Y.Wang, L. Gao, X. Cai, R. Ren, J. Zhu, Z. Chen, S. J. Chen. 2008.Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronicmyeloid leukemia. Proc. Natl. Acad. Sci. USA. 105: 2076-81.
49. Parikh,C. and R. Ren. 2008. Mouse model for NRAS-induced leukemogenesis. MethodsEnzymol. 439:15-24.
50. BaumKJ, R. Ren. 2008. Effect of Ras Inhibition in Hematopoiesis and BCR/ABLLeukemogenesis. J Hematol Oncol. 1:5.
51. Acquaviva,J. X. Chen and R. Ren. 2008. IRF-4 functions as a tumor suppressor in earlyB-cell development. Blood. 110:3798-806.
52. JaganiZ, K. Song, J. L. Kutok, M. R. Dewar, A. Melet, T. Santos, A. Grassian, S.Ghaffari, C. Wu, H. Yeckes-Rodin, R. Ren, K. Miller, R. Khosravi-Far. 2009.Proteasome inhibition causes regression of leukemia and abrogatesBCR-ABL-induced evasion of apoptosis in part through regulation of forkheadtumor suppressors. Cancer Research. 69:6546-55.
53. Cuiffo,B., and R. Ren. 2010. Palmitoylation of oncogenic NRAS is essential forleukemogenesis. Blood. 115:3598-605. PMID: 20200357
54. Jo,S., J. Schatz, J. Acquaviva, H. Singh and R. Ren. 2010. Cooperation betweendeficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoidtumorigenesis. Blood. 116:2759-67. PMID: 20585039
55. Wang,Y.Y., L.J. Zhao, C.F. Wu, P. Liu, L. Shi, Y. Liang, S.M. Xiong, J.Q. Mi, Z.Chen, R. Ren (co-corresponding author), S.J. Chen. 2011. C-KIT mutation cooperates withfull-length AML1-ETO to induce acute myeloid leukemia in mice. Proc. Natl.Acad. Sci. USA. 108: 2450-5. PMID: 21262832
56. Jo,S. and R. Ren. 2012. IRF-4 suppresses BCR/ABL transformation of myeloid cellsin a DNA binding-independent manner. J Biol Chem. 287:1770-8. PMID:22110133
57. Jiao, B., Z.H. Ren, P. Liu, L.J Chen, J.Y. Shi, Y. Dong, J. Ablain, L. Shi, L. Gao, J.P. Hu, R. Ren, H. de Thé, Z. Chen, and S.J. Chen. 2013. 8-CPT-cAMP/all-trans retinoic acid targets t(11;17) acute promyelocytic leukemia through enhanced cell differentiation and PLZF/RARα degradation. Proc. Natl. Acad. Sci. USA. 110:3495-500
58. Liu, Y.J., H.B. Fan, Y. Jin, C.G. Ren, X.E. Jia, L. Wang, Y. Chen, M. Dong, K.Y. Zhu, Z.W. Dong, B.X. Ye, Z. Zhong, M. Deng, T.X. Liu and R. Ren. 2013.Cannabinoid receptor 2suppresses leukocyte inflammatory migration by modulating the JNK/c-Jun/Alox5pathway. J Biol Chem. 288:13551-62.
59. Ren C.G., L. Wang, X.E. Jia, Y.J. Liu, Z.W. Dong, Y. Jin, Y. Chen, M. Deng, Y. Zhou, Y. Zhou, R. Ren(co-corresponding author), W.J. Pan and T.X. Liu. 2013. Activated N-Ras signaling regulates arterial-venous specification in zebrafish. J Hematol Oncol. 6:34 doi: 10.1186/1756-8722-6-34.
60. Fredericks J. and R. Ren. 2013. The role of RAS effectors in BCR/ABL induced chronic myelogenous leukemia. Front Med. 7:452-61.
61. Du T.T., P.F. Xu, Z.W. Dong, H.B. Fan, Y. Jin, M. Dong, Y. Chen, W.J. Pan, R. Ren, T.X. Liu, M. Deng, and Q.H. Huang. 2014. Setdb2 controls convergence and extension movements during zebrafish gastrulation by transcriptional regulation of dvr1. Dev Biol. 392:233-44
62. Wang Y., M. Xiao, X. Chen, L. Chen, P. Wang, H. Yang, S. Ma, J. Zhang, B. Jiao, R. Ren, D. Ye, K. Guan and Y. Xiong. 2015. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. Molecular Cell. 57:662-73
63. Zhao H., P. Liu, R. Zhang, M. Wu, D. Li, X. Zhao, C. Zhang, B. Jiao, B. Chen, Z. Chen and R. Ren. 2015. Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4A.J Hematol Oncol. 8:132:1-14
64. Liu P., B. Jiao, R. Zhang, H. Zhao, C. Zhang, M. Wu, D. Li, X. Zhao, Q. Qiu, J. Li and R. Ren. 2016. Palmitoylacyltransferase Zdhhc9 Inactivation Mitigates Leukemogenic Potential of Oncogenic Nras. Leukemia. 30:1225-8
65. Pan MM, Zhang QY, Wang YY, Liu P, Ren RB, Huang JY, Chen LT, Xi XD, Chen Z, Chen SJ. 2016. Human NUP98-IQCG fusion protein induces acute myelomonocytic leukemia in mice by dysregulating the Hox/Pbx3 pathway. Leukemia. 30:1590-3.
66. Zhang ZG, Wang Q, Kong J, Chen B, Zhu YM, Weng XQ, Shen ZX, Li JM, Wang J, Yan XJ, Li Y, Liang YM, Liu L, Chen XQ, Zhang WG, Yan JS, Hu JD, Shen SH, Chen J, Gu LJ, Pei D, Li Y, Wu G, Zhou X, Ren RB, Cheng C, Yang JJ, Wang KK, Wang SY, Zhang J, Mi JQ, Pui CH, Tang JY, Chen Z, Chen SJ. 2016. Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia. EBioMedicine. 8:173-83
67. Jin Y, Zhou J, Xu F, Jin B, Cui L, Wang Y, Du X, Li J, Li P, Ren R, Pan J. 2016 Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. J Clin Invest. 126:3961-3980
68. Li D., X. Zhao, R. Zhang, H. Zhao, B. Jiao, Q. Qiu, M. Wu, P. Liu, R. Ren. 2016. BCR/ABL can promote CD19 cell growth but not render them long-term stemness. Stem Cell Investigation. 3:85
69. Jiang J, Gui F, He Z, Li L, Li Y, Li S, Wu X, Deng Z, Sun X, Huang X, Huang W, Han S, Zhang T, Wang Z, Jiao B, Song S, Wang HR, Chen L, Zhou D, Liu Q, Ren R (co-corresponding author), Zhang J, Deng X. 2017. Targeting BRK-positive breast cancers with small molecule kinase inhibitors. Cancer Res. 77:175-186
70. Wu M., J. Huang, J. Zhang, C. Benes, B. Jiao, R. Ren. 2017. N-Arachidonoyl Dopamine Inhibits NRAS Neoplastic Transformation by Suppressing Its Plasma Membrane Translocation. Molecular Cancer Therapeutics. 16:57-67
